A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
Hypertension

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion criteria: aged at least 60 years old mean SBP greater than 140 mmHg and mean DBP less than or equal to 95 mmHg 24-hour mean ambulatory SBP greater than 125 mmHg hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks willing and able to provide written informed consent Exclusion criteria: women of child-bearing potential who are NOT practicing acceptable means of birth control known or suspected secondary hypertension mean SBP equal to or greater than 200 mmHg hepatic and/or renal dysfunction as defined by the following laboratory parameters: bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney clinically relevant hypokalemia or hyperkalemia uncorrected volume or sodium depletion primary aldosteronism hereditary fructose intolerance biliary obstructive disorders patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists history of drug or alcohol dependency within the previous six months chronic administration of any medication known to affect blood pressure, other than the trial medication concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form. symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV) unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to informed consent stroke less than six months prior to informed consent sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM known allergic hypersensitivity to any component of the formulations under investigation concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as less than 80% or more than 120%) during the run-in period current treatment with any antihypertensive agent any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide
Sites / Locations
- A.C.Z. Antwerpen/Stuyvenberg
- Boehringer Ingelheim Investigational Site
- A.Z. VUB
- C.H.U. Liège (Ourthe-Amblève)
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Diacor
- Kiljava Medical Research
- Hämeenlinnan lääkäriasema Oy, Linnan klinikka
- Boehringer Ingelheim Investigational Site
- Kouvolan lääkäriasema
- Hatanpään terveyskeskussairaala
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Hôpital de la Timone
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Deutsche Klinik für Diagnostik GmbH
- Evangelisches Krankenhaus
- 19 Redwood View
- Adelaide and Meath Hospitals (incorrporating NCH)
- Boehringer Ingelheim Investigational Site
- Cardioperfect Research Room
- Beaumont Park Clinic
- Boehringer Ingelheim Investigational Site
- Ospedale S. Luigi - S. Currò
- Università di Ferrara
- Az. Osped. Universitaria "Osp. Riuniti"
- Azienda Ospedaliera "Maggiore della Carità"
- Ospedale Scillesi d'America
- Ospedale Civile
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Avda. Menendez Pidal, s&n
- Hospital Gral de Jerez de la Frontera
- Cardiology Service